Season 7, Episode 5 - Why does WHO engagement with Steatotic Liver Disease matter?
This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition
Moderator: Jeffrey Lazarus
Faculty: Mazen Noureddin, Shira Zelber-Sagi, Kremlin Wickramasinghe
The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.
Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.
Related episodes:
- EASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscape
- EASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II study
- EASL Studio S6E1: Do we solve MASLD by treating obesity?
- EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathways
- EASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHO
- EASL Studio S4E8: The central role of alcohol and food policies on liver health
